Fortress Biotech Inc represents values of innovation, collaboration, and dedication to improving patients' lives. With a corporate philosophy focused on advancing and commercializing novel therapies, the company aims to address unmet medical needs in various therapeutic areas. Fortress Biotech Inc fosters strategic partnerships and leverages its diverse and experienced team to develop cutting-edge treatments. By nurturing a culture of excellence and a commitment to delivering value to stakeholders, Fortress Biotech Inc aims to be at the forefront of healthcare innovation.

Fortress Biotech Inc primarily operates in the United States.

Fortress Biotech Inc has achieved several significant milestones in its journey. The company has successfully advanced multiple clinical programs, including the FDA approval of its targeted therapy for a certain type of lymphoma. Additionally, Fortress Biotech has established strategic collaborations with renowned pharmaceutical companies to further develop its innovative pipeline and expand its global reach. With a strong focus on research and development, Fortress Biotech has also made notable progress in advancing novel therapies for rare diseases, oncology, and dermatology. Overall, the company's dedication to scientific excellence and strategic partnerships has propelled it to achieve noteworthy milestones in the biotech industry.

Fortress Biotech Inc is a renowned biopharmaceutical company with a rich history and remarkable background. Founded in 2006, the company focuses on acquiring, developing, and commercializing various innovative pharmaceutical and biotechnology products. Fortress Biotech Inc operates through a unique business model, collaborating with a diverse network of partner companies to advance a wide range of therapeutic areas. With a strong commitment to improving patients' lives, the company's robust pipeline includes treatments for rare diseases, dermatology, oncology, and more. Fortress Biotech Inc has consistently aimed to deliver groundbreaking medical solutions and create value for both patients and shareholders.

The main competitors of Fortress Biotech Inc in the market include Celgene Corporation, Novartis AG, Amgen Inc, Gilead Sciences, and Biogen Inc.

Fortress Biotech Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Fortress Biotech Inc. focuses on acquiring, developing, and commercializing pharmaceutical and biotechnology products. As a biopharmaceutical company, Fortress Biotech Inc. collaborates with various academic and research institutions, as well as other companies, to enhance the development and commercialization of new therapies and treatments. By leveraging its extensive network and expertise, Fortress Biotech Inc. aims to provide innovative solutions to address unmet medical needs. With a diverse portfolio of product candidates targeting various disease indications, the company aims to deliver value to patients, healthcare providers, and stakeholders in the biotechnology industry.

De Fortress Biotech K/W is -0,15.

De Fortress Biotech KUV is 0,19.

De AlleAktien Kwaliteitsscore voor Fortress Biotech is 5/10.

De verwachte Fortress Biotech omzet is 75,40 mln. USD.

De verwachte Fortress Biotech winst is -95,70 mln. USD.

Fortress Biotech Inc is a biopharmaceutical company based in the USA. It follows a unique business model, establishing or acquiring companies involved in biopharmaceutical research, development, and marketing. It has a portfolio of subsidiaries and investments operating in various areas of the healthcare industry. The company's subsidiaries and pillars consist of different disciplines, including drug development and research, diagnostics, and medical devices. Fortress Biotech utilizes the knowledge and experience of its subsidiaries to develop new products and procedures aimed at improving patient health and well-being. The company is able to serve a fast-paced market while keeping costs low by accessing publicly funded research and existing scientific infrastructure. Some of its subsidiaries include Aevitas Therapeutics, specializing in cancer therapies, and Mustang Bio, specializing in gene therapies. Fortress Biotech also has a stake in Caelum Biosciences, specializing in blood cancer treatments, and Journey Medical Corporation, specializing in dermatological diseases. The company's business model reduces the risk of failures in research and development by leveraging the knowledge and infrastructure of its subsidiaries. By collaborating and sharing resources, the company can keep costs low while still bringing innovative drugs to the market.

Fortress Biotech keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Fortress Biotech of het bedrijf keert geen dividend uit.

De ISIN van Fortress Biotech is US34960Q1094.

Het WKN van Fortress Biotech is A14SJV.

De ticker van Fortress Biotech is FBIO.

Binnen de laatste 12 maanden betaalde Fortress Biotech een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Fortress Biotech naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Fortress Biotech is momenteel .

Fortress Biotech betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Fortress Biotech betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Fortress Biotech wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Fortress Biotech van 11-7-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 11-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 11-7-2024.

In het jaar 2023 heeft Fortress Biotech 0 USD aan dividenden uitgekeerd.

De dividenden van Fortress Biotech worden in USD uitgekeerd.